Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | a small-molecule pocket: olpasiran, pelacarsen | 0.60 |
| trials ClinicalTrials.gov | 14 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 45 Parkinson's papers of 16,953 | 0.50 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9184
Sealed predictions
- LPA in dopamine neurons, braak+0.10 (p 0.802) → +0.51 (p 0.160)receipt 9190
Swarm cases
receipt 9190: LPA in dopamine neurons, braak
- power
- full sample +0.29 (p 0.235, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.34 (p 0.161, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.19 (p 0.450, n 18). could be the mix.
- skeptic
- leave-one-out range +0.21 to +0.46, sign flips 0; without severely affected donors +0.29 (p 0.235, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LPA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts